The firm sees the new panel as an important step forward in its strategy to further penetrate the molecular diagnostics market with its qPCR products.
Researchers from Protagen, Targos, and elsewhere have identified autoantibody biomarkers specific to patients diagnosed with prostate cancer.
Researchers in Belgium and the UK showed that their custom viral panel on Thermo Fisher's TaqMan qPCR array card is effective in samples from immunocompromised patients.
The product introduction comes about two years after the company merged with AmpliDiag and Genewave.
CEO Lars Kongsbak said that the proceeds will be used to strengthen the company's capital resources and to expand its inventory in light of growing demand for its qPCR arrays, miRcury microRNA microarrays, and other products and services.
Lonza is distributing Bar Harbor BioTechnology's new tools under an exclusive agreement.
The UK's Nuffield Council on Bioethics says genetically modifying human embryos could be morally permissible, according to the Guardian.
A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.
The Wall Street Journal likens a prototype developed by Synthetic Genomics to a "biological fax machine."
In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.